| Similar Articles |
|---|
 |
The Motley Fool
October 19, 2009
Rich Smith |
This Just In: Upgrades and Downgrades Merriman Curhan Ford thinks Geron could as much as double off today's price, primarily in response to successful data on GRN163L, a treatment that targets cancer agent telomerase.   |
The Motley Fool
May 20, 2009
Rich Smith |
This Just In: Upgrade or Downgrade With just two weeks to go before its new "Pre" cell phone hits the street, Needham & Co. slaps Palm with an "underperform" rating. |
The Motley Fool
February 10, 2010
Rich Smith |
This Just In: Upgrades and Downgrades It wasn't enough that game maker Electronic Arts had to suffer the injury of a 9% stock drop yesterday; it also bore the brunt of an insult from Needham & Co., which pulled its buy rating on the stock. |
The Motley Fool
January 20, 2012
Dan Caplinger |
Can Geron Recover in 2012? Let's look at this year's prospects for this company. |
The Motley Fool
August 2, 2010
Brian Orelli |
Back in Love With Geron Investors' love / hate relationship with Geron is back in the worship phase, with the stem cells company up 17% on Friday and nearly an additional 10% or so today. |
The Motley Fool
June 29, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Needham needs a price check in aisle II-VI. Shareholders of laser-equipment maker II-VI are jumping for joy this week -- and the shares jumped by 2% yesterday |
The Motley Fool
June 7, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Needham & Company advises investors to sell stock in First Solar and buy shares of Solarfun Power Holdings instead. |
The Motley Fool
November 15, 2011
Brian Orelli |
When Giving Up Is a Good Move in Biotech Geron calls it quits with stem cells. |
The Motley Fool
May 3, 2005
Charly Travers |
Is Geron a Rule Breaker? At the forefront of stem cell research, can the company live up to its lofty potential? Geron's science is hot. Its stock is not. |
The Motley Fool
August 19, 2010
Brian Orelli |
The Mice Can Walk! Remember you're essentially buying a lottery ticket investing in this or any other unproven early stage biomedical technology. |
The Motley Fool
December 23, 2011
Brian Orelli |
Geron's Hurry-Up-and-Wait Strategy Clinical trials started, now the waiting begins. |
The Motley Fool
October 12, 2010
Travis Hoium |
Geron Shares Popped: What You Need to Know Geron shares jumped 10% after the company announced that its first patient has enrolled in the company's stem cell clinical trial. |
The Motley Fool
August 27, 2007
Brian Orelli |
Repairing a Broken Heart Stem cells may be the new cure. If research continues on track, Geron expects to ask FDA to start clinical trials late next year or in early 2009. Investors, take note. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
November 17, 2008
Rich Smith |
This Just In: Upgrades and Downgrades Bank of America analysts aren't terribly impressed with most drug companies. But they did give thumbs up to two. |
The Motley Fool
December 8, 2011
Dan Caplinger |
Has Geron Become the Perfect Stock? Geron has a modest pipeline of cancer drugs, including imetelstat, which is currently in phase 2 clinical trials. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
The Motley Fool
January 23, 2009 |
2 Stocks Hitting High Notes These stocks are bucking the trend and hitting new highs. Take a look at: Geron... American Science & Engineering... |
The Motley Fool
November 9, 2004
Charly Travers |
Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works. |
The Motley Fool
July 26, 2004
Brian Gorman |
Stem Cell Researcher a Risk Geron could benefit from a new U.S. president, but in the end, studies of embryonic stem cells may or may not yield breakthroughs, so buying their stock now would be a gamble. |
Bio-IT World
Dec 2005/Jan 2006
Maureen McDonough |
The Century of the Cell Like most new life science industries, the stem cell business landscape looks like a maze. There are many paths, turns, and dead-ends, but it is quite possible that there will be more than one route to the finish line. |
The Motley Fool
April 3, 2006
Seth Jayson |
No Stemming the Flow of Shares Another year, another large dollop of shares to water down the juice at StemCells. This company excels at burning money, as its cash flow statements show. Invest accordingly. |
The Motley Fool
November 30, 2004
Rich Smith |
Breaking Rules and Saving Lives Cord blood offers an ethical means of using stem cells to heal illness. While two top companies in the field are private, over the counter traded Cryo-Cell lost as much money as it collected in revenues last year. |
The Motley Fool
May 26, 2009
Brian Orelli |
A Less-Risky Stem Cell Play Life Technologies is a clear leader in stem cell reagents. |
The Motley Fool
April 14, 2008
Brian Orelli |
Stem Cells Show Off The FDA moves closer to setting up stem cell clinical trials, setting guidelines that put treatment safety first and foremost. |
The Motley Fool
March 17, 2005
Travers & Mock |
Stock Madness 2005: Geron vs. UTStarcom Biotech faces off against telecom in this contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness. -- which company gets your vote? |
The Motley Fool
March 16, 2009
Rick Aristotle Munarriz |
5 Stocks Under $10 With so many stocks trading in the single digits these days, there are plenty of stocks to go around. Here are five that have promise: Bare Escentuals... Sirius XM Radio... Focus Media... Geron... Ford... |
The Motley Fool
September 29, 2010
Brian Orelli |
Careful What You Wish For, Stem Cell Investors Investors seem to have forgotten about fundamentals. |
The Motley Fool
July 22, 2005
Karl Thiel |
Cancer Drug: A Shot at Success Cancer vaccine pioneer Dendreon delivered news yesterday that its investors have been anxiously awaiting: final three-year survival data from a phase 3 study of Provenge, the company's flagship prostate cancer vaccine. |
The Motley Fool
January 12, 2004
Dave Marino-Nachison |
All Eyes on Dendreon The cancer fighter's shares rocketed today on good news out of Phase III trials. |
Information Today
May 14, 2015 |
NPG Announces Spinal Cord Journal Nature Publishing Group introduced a quarterly, online-only journal, Spinal Cord Series and Cases, in collaboration with the International Spinal Cord Society. |
The Motley Fool
July 14, 2011
Rich Smith |
What's All the Fuss About Stem Cells? Stocks are up on news of Sweden's miracle meatball. Over the weekend, Swedish researchers announced the successful transplant of an artificial trachea to a patient whose own organ had been ravaged by cancer. |
The Motley Fool
November 14, 2008
Brian Orelli |
Pfizer Takes the Plunge Into Stem-Cell Research The world's largest drugmaker by market cap announced today that it's forming a unit to focus on stem cells. |
The Motley Fool
February 2, 2010
Rich Smith |
Ground Floor -- Going Up! If you're beginning to think that trying to "get in on the ground floor" is hopeless ... well, there is an alternative: Take the escalator to the second floor, and enter there. |
The Motley Fool
December 1, 2008
Brian Orelli |
Obama Can't Save Stem Cell Companies While government-sponsored research on embryonic stem cells might eventually help scientists better understand all stem cells, it's not likely to help the companies right now. |
